SCHEMBL6500349

SCHEMBL6500349

CC(=O)Nc1ccc(-c2cccc(-n3cc(NC(N)=O)c(C(N)=O)n3)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 3/20 0.46
KDM4E B2RXH2 2/20 0.46
OGT O15294 2/20 0.46
NPC1 O15118 1/20 0.46
PKM P14618 1/20 0.46
RAB9A P51151 1/20 0.46
ITK Q08881 1/20 0.45
HDAC1 Q13547 3/20 0.43
SCN9A Q15858 1/20 0.42
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
KMT2A Q03164 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6467744 0.93 SMN1; SMN2 (0.48) SMN1; SMN2LMNAMAPTKDM4ENPC1
SCHEMBL6504845 0.88 ITK (0.46) SMN1; SMN2LMNAMAPTKDM4ENPC1
SCHEMBL6501255 0.87 ITK (0.45) SMN1; SMN2LMNAMAPTKDM4ENPC1
SCHEMBL6499548 0.87 ITK (0.45) SMN1; SMN2LMNAMAPTKDM4ENPC1
SCHEMBL6466388 0.87 PIP4K2A (0.47) KDM4EITKSCN9AALDH1A1HPGD
SCHEMBL6470665 0.86 ITK (0.46) SMN1; SMN2LMNAMAPTKDM4ENPC1
SCHEMBL6498355 0.86 KDM4E (0.47) LMNAMAPTKDM4EITKSCN9A
SCHEMBL6506096 0.86 SCN9A (0.48) SMN1; SMN2LMNAMAPTKDM4ERAB9A
SCHEMBL6498382 0.85 ITK (0.45) SMN1; SMN2LMNAMAPTKDM4ENPC1
SCHEMBL6502813 0.85 ITK (0.45) SMN1; SMN2LMNAMAPTKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation PHARMACIA AND UPJOHN COMPANY LLC 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation IL4, ARG2, CASP4 SMN1; SMN2 3519/4885LMNA 1826/4885MAPT 1906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.